Search Results - Sridharan Gururangan

Refine Results
  1. 1
    Social Functioning and Facial Expression Recognition in Survivors of Pediatric Brain Tumors

    Social Functioning and Facial Expression Recognition in Survivors of Pediatric Brain Tumors by Melanie J. Bonner, Kristina K. Hardy, Victoria W. Willard, Kelly K. Anthony, M. Hood, Sridharan Gururangan

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration

    Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration by Jessica Cohen‐Pfeffer, Sridharan Gururangan, Thomas Lester, Daniel A. Lim, Adam J. Shaywitz, Manfred Westphal, Irene Slavc

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Best practices for the use of intracerebroventricular drug delivery devices

    Best practices for the use of intracerebroventricular drug delivery devices by Irene Slavc, Jessica Cohen‐Pfeffer, Sridharan Gururangan, Jeanne Krauser, Daniel A. Lim, Marcos Vinícius Calfat Maldaun, Christoph Schwering, Adam J. Shaywitz, Manfred Westphal

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

    Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma by David A. Reardon, James J. Vredenburgh, April Coan, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, Sith Sathornsumetee, Jeremy N. Rich, James E. Herndon, Henry S. Friedman

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

    Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma by David A. Reardon, Merrill J. Egorin, Annick Desjardins, James J. Vredenburgh, Jan H. Beumer, Theodore Lagattuta, Sridharan Gururangan, James E. Herndon, August J. Salvado, Henry S. Friedman

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

    Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma by David A. Reardon, Jennifer A. Quinn, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, Michael Badruddoja, James E. Herndon, Jeannette M. Dowell, Allan H. Friedman, Henry S. Friedman

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Short-Term Efficacy of Methylphenidate: A Randomized, Double-Blind, Placebo-Controlled Trial Among Survivors of Childhood Cancer

    Short-Term Efficacy of Methylphenidate: A Randomized, Double-Blind, Placebo-Controlled Trial Among Survivors of Childhood Cancer by Raymond K. Mulhern, Raja B. Khan, Stuart L. Kaplan, Susan Helton, Robbin Christensen, Melanie J. Bonner, Ronald T. Brown, Xiaoping Xiong, Sengjie Wu, Sridharan Gururangan, Wilburn E. Reddick

    Published 2004
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study

    Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study by Sridharan Gururangan, Susan Chi, Tina Young Poussaint, Arzu Onar‐Thomas, Richard J. Gilbertson, Sridhar Vajapeyam, Henry S. Friedman, Roger J. Packer, Brian Rood, James M. Boyett, Larry E. Kun

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

    Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma by David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, James E. Herndon, Jennifer Marcello, J. Norfleet, Roger E. McLendon, John H. Sampson, Henry S. Friedman

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience

    Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience by Christopher D. Turner, Sridharan Gururangan, James D. Eastwood, Krystal S. Bottom, Melody Watral, Rodney Beason, Roger E. McLendon, Allan H. Friedman, Sandra Tourt-Uhlig, Langdon L. Miller, Henry S. Friedman

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

    Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma by David A. Reardon, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, Anuradha Bulusu, Stevie Threatt, Allan H. Friedman, James J. Vredenburgh, Henry S. Friedman

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

    Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy by David A. Reardon, Annick Desjardins, Katherine B. Peters, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, April Coan, Stevie Threatt, Allan H. Friedman, Henry S. Friedman

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

    Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma by Sith Sathornsumetee, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, Jennifer Marcello, James E. Herndon, Alyssa Mathe, Marta Hamilton, Jeremy N. Rich, J. Norfleet, Sridharan Gururangan, Henry S. Friedman, David A. Reardon

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

    Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study by David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Sith Sathornsumetee, Roger E. McLendon, James E. Herndon, Jennifer Marcello, J. Norfleet, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Phase I Trial of Single-Dose Temozolomide and Continuous Administration of <i>O</i>6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report

    Phase I Trial of Single-Dose Temozolomide and Continuous Administration of <i>O</i>6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report by Alberto Broniscer, Sridharan Gururangan, Tobey J. MacDonald, Stewart Goldman, Roger J. Packer, Clinton F. Stewart, Dana Wallace, Mary K. Danks, Henry S. Friedman, Tina Young Poussaint, Larry E. Kun, James M. Boyett, Amar Gajjar

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

    Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma by James J. Vredenburgh, Annick Desjardins, James E. Herndon, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, Melissa Wagner, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Temozolomide in Children with progressive low-grade glioma1

    Temozolomide in Children with progressive low-grade glioma1 by Sridharan Gururangan, Michael J. Fisher, Jeffrey C. Allen, James E. Herndon, Jennifer A. Quinn, David A. Reardon, James J. Vredenburgh, Annick Desjardins, Peter C. Phillips∥, Melody Watral, Jeanne Krauser, Allan H. Friedman, Henry S. Friedman

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

    Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy by David A. Reardon, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Jeremy N. Rich, Roger E. McLendon, James E. Herndon, Jennifer Marcello, Stevie Threatt, Allan H. Friedman, James J. Vredenburgh, Henry S. Friedman

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

    Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma by David A. Reardon, James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Jennifer Marcello, James E. Herndon, Roger E. McLendon, Dorothea Janney, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma

    Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma by Sridharan Gururangan, Jeanne Krauser, Melody Watral, Tim Driscoll, Nicole Larrier, David A. Reardon, Jeremy N. Rich, Jennifer A. Quinn, James J. Vredenburgh, Annick Desjardins, Roger E. McLendon, Herbert E. Fuchs, Joanne Kurtzberg, Henry S. Friedman

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: